According
to the World Health Organization, depression is a major cause of disease burden
worldwide, affecting an estimated 350 million people.
According to the National Institutes of Mental
Health, in 2014, an estimated 15.7 million adults aged 18 or older in the
United States had at least one major depressive episode in the past year.
A new meta-analysis published in Translational
Psychiatry supports
the link between intake of EPA and DHA omega-3
fatty acids, the kind found in fish, and reduction in major depressive disorder
(MDD).
The meta-analysis includes 13 studies with 1233
participants and, according to the authors, showed a benefit for EPA and DHA
comparable to effects reported in meta-analyses of antidepressants.
The present meta-analysis observed a beneficial overall
effect of omega-3 PUFA supplementation in patients with MDD according to
diagnostic criteria, which seemed larger in studies that supplemented higher
doses of EPA and included patients taking antidepressants. Future
precision/personalized medicine trials should establish
whether possible interactions between EPA and antidepressants could provide
targets to improve antidepressant response and its prediction. Nevertheless,
potential long-term biochemical side effects of high-dosed add-on EPA
supplementation should be carefully monitored.
According to the study's lead author Dr. RJT
Mocking, Program for Mood Disorders, Department of Psychiatry, Academic Medical
Center, University of Amsterdam, The Netherlands, "This new meta-analysis nuances earlier
research on the importance of long chain omega-3s in MDD."
Article courtesy medical news
today


